GLPwatch
Bydureon for Gastroparesis
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCBydureon (exenatide) is not FDA-approved for gastroparesis, and any use for this condition is off-label or investigational. Research shows mixed findings, with one study noting exenatide delays gastric emptying in type 2 diabetes but not in gastroparetic patients, while another explores its effects on postprandial symptoms.
AI summary of the sources below.
| Drug | Bydureon (exenatide) |
|---|---|
| Condition | Gastroparesis |
| Approval status | Investigational / off-label |
| Research papers | 3 |
Bydureon is not FDA-approved for gastroparesis; the research below reflects investigational or off-label study only.
Research on exenatide for gastroparesis (3)
- Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
- Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.
- The effect of exenatide and erythromycin on postprandial symptoms and their relation to gastric functions.